Edesa Biotech is trading at $4.69, up 10.87% from the September 11 close of $4.23; the catalyst remains unclear.
- No new company-specific announcement was identified for September 14, 2026.
- The latest clearly reported financing news was the August 19 public-offering pricing announcement.
- The broader market is weaker pre-market, with the Nasdaq Composite down 1.42%; the move may reflect low-liquidity trading or a delayed reaction to prior developments.